Xylem (XYL) official guidance

Full-year 2026 adjusted EBITDA margin is expected to be approximately 23.2 percent, an increase of 100 basis points versus Xylem’s 2025 adjusted results.

EBITDA margin is expected to be 23.1%-23.5%, versus the prior guide of 22.9%-23.3%.

Full-year 2026 adjusted EBITDA margin is expected to be approximately 23.1 to 23.5 percent, an increase of 90 to 130 basis points from Xylem’s 2025 adjusted results.

EBITDA margin is expected to remain at 22.9%-23.3%.

Full-year 2026 adjusted EBITDA margin is expected to be approximately 22.9 to 23.3 percent, an increase of 70 to 110 basis points from Xylem’s 2025 adjusted results.

EBITDA margin is expected to be 22.9%-23.3%.

Full-year 2026 adjusted EBITDA margin is expected to be approximately 22.9 to 23.3 percent, an increase of 70 to 110 basis points from Xylem’s 2025 adjusted results.

Full-year 2026 adjusted EBITDA margin is expected to be approximately 23.2 percent, an increase of 100 basis points versus Xylem’s 2025 adjusted results.

This represents 90 basis points-130 basis points of expansion versus the prior year, driven by productivity, volume, and price more than offsetting inflation, as well as investments in the business.

Full-year 2026 adjusted EBITDA margin is expected to be approximately 23.1 to 23.5 percent, an increase of 90 to 130 basis points from Xylem’s 2025 adjusted results.

This represents 70 basis points to 110 basis points of expansion versus the prior year, driven by productivity and price more than offsetting inflation as well as investments in the business.

Full-year 2026 adjusted EBITDA margin is expected to be approximately 22.9 to 23.3 percent, an increase of 70 to 110 basis points from Xylem’s 2025 adjusted results.

This represents 70-110 basis points of expansion versus the prior year, driven by productivity, volume, and price offsetting inflation, with productivity continuing to benefit from our simplification efforts.

This results in full-year adjusted earnings per share of $5.40 to $5.45, down from the previous guidance range of $5.55 to $5.70.

Our strong first half performance, along with the benefits from share repurchases and higher margins, more than offset the revenue headwind from electric metering delays and gives us confidence to raise the EPS range from $5.35-$5.60 to $5.55-$5.70.

This results in full-year adjusted earnings per share of $5.55 to $5.70, up from the previous guidance range of $5.35 to $5.60.

Despite the benefit from share repurchases, we've chosen to keep our EPS range unchanged at $5.35-$5.60, reflecting a prudent approach to guidance in an uncertain macro environment and not a change to our outlook for the year.

This results in full-year adjusted earnings per share of $5.35 to $5.60, in line with the previous guidance range.

This yields an EPS range of $5.35-$5.60, up 8% at the midpoint over the prior year.

Full-year free cash flow margin is expected to be approximately 10.2 percent, versus 10.2 to 11.0 percent previously guided.

Cash flow generation was strong in the first half, and we remain on target to achieve our low double-digit free cash flow margin for the year.

Full-year free cash flow margin is still expected to be approximately 10.2 to 11.0 percent.

Full-year free cash flow margin is still expected to be approximately 10.2 to 11.0 percent.

Full-year free cash flow margin is expected to be approximately 10.2 to 11 percent.

Xylem now forecasts full-year 2026 revenue of approximately $8.95 billion, down 1 percent year over year on a reported basis, versus prior guidance of up 2 percent, and flat on an organic basis, versus prior guidance of up 2 to 3 percent.

Full-year reported revenue is now expected to be roughly $9.2 billion which delivers revenue growth of approximately 2%, while organic revenue growth will be in the 2%-3%, versus prior guidance of 2%-4%.

Xylem now forecasts full-year 2026 revenue of approximately $9.2 billion, up approximately 2 percent on a reported basis, versus 2 to 3 percent previously guided, and up approximately 2 to 3 percent on an organic basis, versus 2 to 4 percent previously guided.

While organic revenue growth of 2%-4% remains unchanged versus prior guidance.

Xylem now forecasts full-year 2026 revenue of approximately $9.2 to $9.3 billion, up approximately 2 to 3 percent on a reported basis, versus 1 to 3 percent previously guided, and up approximately 2 to 4 percent on an organic basis, as previously guided.

The growth outlook by segment translates into 2026 full year revenue of $9.1 billion-$9.2 billion, resulting in revenue growth of 1%-3% and organic revenue growth of 2%-4%.

Xylem forecasts full-year 2026 revenue of approximately $9.1 to $9.2 billion, up approximately 1 to 3 percent on a reported basis and up approximately 2 to 4 percent on an organic basis.

Xylem now forecasts full-year 2026 revenue of approximately $8.95 billion, down 1 percent year over year on a reported basis, versus prior guidance of up 2 percent, and flat on an organic basis, versus prior guidance of up 2 to 3 percent.

Full-year reported revenue is now expected to be roughly $9.2 billion which delivers revenue growth of approximately 2%, while organic revenue growth will be in the 2%-3%, versus prior guidance of 2%-4%.

Xylem now forecasts full-year 2026 revenue of approximately $9.2 billion, up approximately 2 percent on a reported basis, versus 2 to 3 percent previously guided, and up approximately 2 to 3 percent on an organic basis, versus 2 to 4 percent previously guided.

Full year reported revenue is now expected to be $9.2 billion-$9.3 billion, up from the prior guide of $9.1 billion-$9.2 billion, which delivers revenue growth of 2%-3%.

Xylem now forecasts full-year 2026 revenue of approximately $9.2 to $9.3 billion, up approximately 2 to 3 percent on a reported basis, versus 1 to 3 percent previously guided, and up approximately 2 to 4 percent on an organic basis, as previously guided.

The growth outlook by segment translates into 2026 full year revenue of $9.1 billion-$9.2 billion, resulting in revenue growth of 1%-3% and organic revenue growth of 2%-4%.

Xylem forecasts full-year 2026 revenue of approximately $9.1 to $9.2 billion, up approximately 1 to 3 percent on a reported basis and up approximately 2 to 4 percent on an organic basis.